Refreshing results…
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Download from aacrjournals.orgA RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Download from doi.orgMissing publications? Search for publications with a matching author name.